Showing results (21-30 of 59) with videos related to
Sort By:
Pageof 6
Depression and Anxiety|July 18, 2006
Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalationMadelaine M Wohlreich, Craig H Mallinckrodt, Apurva Prakash, et al.Journal of Psychiatric Research|November 8, 2005
Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose rangeCraig H Mallinckrodt, Apurva Prakash, Anne C Andorn, et al.Current Therapeutic Research, Clinical and Experimental|March 29, 2014
Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting dosesDavid L Dunner, Madelaine M Wohlreich, Craig H Mallinckrodt, et al.BMC Psychiatry|September 10, 2004
The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trialsCraig H Mallinckrodt, Joel Raskin, Madelaine M Wohlreich, et al.The Journal of Clinical Psychiatry|July 18, 2006
Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trialsSusan G Kornstein, Madelaine M Wohlreich, Craig H Mallinckrodt, et al.Journal of Affective Disorders|June 20, 2006
Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patientsDonna E Stewart, Madelaine M Wohlreich, Craig H Mallinckrodt, et al.Neuropsychobiology|November 27, 2007
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)Craig H Mallinckrodt, Apurva Prakash, John P Houston, et al.Journal of the National Medical Association|April 1, 2006
Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacyRahn K Bailey, Craig H Mallinckrodt, Madelaine M Wohlreich, et al.Journal of Psychiatric Research|December 14, 2004
Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studiesStephen K Brannan, Craig H Mallinckrodt, Michael J Detke, et al.Journal of Clinical Psychopharmacology|November 12, 2005
An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approachesMadelaine M Wohlreich, James M Martinez, Craig H Mallinckrodt, et al.Pageof 6